Metalloproteinases and Hypertrophic Cardiomyopathy: A Systematic Review
Giuseppe Filiberto Serraino,
Federica Jiritano,
Davide Costa,
Nicola Ielapi,
Desirèe Napolitano,
Pasquale Mastroroberto,
Umberto Marcello Bracale,
Michele Andreucci,
Raffaele Serra
Affiliations
Giuseppe Filiberto Serraino
Department of Experimental and Clinical Medicine, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy
Federica Jiritano
Department of Experimental and Clinical Medicine, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy
Davide Costa
Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
Nicola Ielapi
Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
Desirèe Napolitano
Ph.D. Student “Digital Medicine” Ph.D. Programm-Magna Graecia, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy
Pasquale Mastroroberto
Department of Experimental and Clinical Medicine, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy
Umberto Marcello Bracale
Department of Public Health, Vascular Surgery Unit, University of Naples “Federico II”, 80126 Naples, Italy
Michele Andreucci
Department of Health Sciences, Nephrology Unit, University of Catanzaro, 88100 Catanzaro, Italy
Raffaele Serra
Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy
Hypertrophic cardiomyopathy (HCM) is a genetic condition determined by an altered collagen turnover of the extracellular matrix. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are abnormally released in patients with HCM. The purpose of this systematic review was to thoroughly summarize and discuss the existing knowledge of MMPs profile in patients with HCM. All studies meeting the inclusion criteria (detailed data regarding MMPs in patients with HCM) were selected, after screening the literature from July 1975 to November 2022. Sixteen trials that enrolled a total of 892 participants were included. MMPs–particularly MMP2—levels were found higher in HCM patients compared to healthy subjects. MMPs were used as biomarkers after surgical and percutaneous treatments. Understanding the molecular processes that control the cardiac ECM’s collagen turnover allows for a non-invasive evaluation of HCM patients through the monitoring of MMPs and TIMPs.
